Cyclin D1 is one of the most commonly overexpressed oncogenes in breast cancer; yet, it is not clear whether cyclin D1 alone is capable of causing malignant transformation of mammary epithelial cells. Here, we show that ectopic expression of cyclin D1 in benign mouse mammary epithelial cells promotes cell proliferation, anchorage-independent growth in soft agar, and tumorigenesis in severe combined immunodeficient mice. To address the possible interaction of cyclin D1 and c-myc in malignant transformation, we used cyclin D1/c-myc dual-expressing clones, which displayed more aggressive and invasive phenotype than cyclin D1-expressing clones. These data provide evidence that overexpression of cyclin D1 or coexpression with c-myc could cause invasive malignant transformation of benign mouse mammary epithelial cells. Furthermore, microarray analysis of cyclin D1 and cyclin D1/c-myc clones showed that these two tumorproducing clones might use distinct invasive pathways. In summary, overexpression of cyclin D1 may commit mammary epithelia to a tumor-prone phenotype in which cooperation with other genes, such as synergy with c-myc, may lead to a more aggressive phenotype. [Cancer Res 2007;67(8):3698-707] 
Introduction
The cyclin D1 oncogene is overexpressed or amplified at high frequencies in a variety of human cancers. In human breast cancer, such alterations are found in f50% of cases (1) . Targeted deletion of the cyclin D1 gene has shown its essential role in normal mammary gland development (2) (3) (4) . Overexpression of cyclin D1 in the mammary gland of the transgenic mice driven by mouse mammary tumor virus (MMTV) long terminal repeat causes hyperplasia, but adenocarcinomas develops after a long latency (18 months) and at a low penetrance (5) . Animal studies using knockout, knock-in, and combined knockout with transgenic approaches suggest that mammary carcinogenesis initiated by several oncogenes, such as neu and Ha-ras, are solely dependent on cyclin D1 (4-6), which further strengthens the importance of cyclin D1 in breast cancer formation.
Studies using in vitro culture systems to test the oncogenic potential of cyclin D1 were largely uninformative and showed conflicting data reporting three different conclusions in both fibroblastic and epithelial cell systems: (a) that overexpression of cyclin D1 alone only transforms fibroblasts, such as Rat6 and NIH3T3, that can form tumors in severe combined immunodeficient (SCID) mice (7, 8) ; (b) that overexpression of cyclin D1 in Rat6 and NIH3T3 fibroblasts can promote cell proliferation, but cyclin D1 alone is not capable of promoting tumorigenesis (9) ; (c) that cyclin D1 inhibits cell proliferation and induces apoptosis in mouse mammary epithelial cells (10) . Clearly, these conflicting data raise an issue whether cyclin D1 alone is capable of causing malignant transformation of cells, especially mammary epithelial cells.
Like cyclin D1, the c-myc oncogene has also been shown to be aberrantly expressed or amplified in most, if not all, types of human malignancy, including breast cancer, suggesting that the c-Myc oncoprotein plays an important role in cancer development and progression (11) . MMTV-c-myc transgenic mice develop mammary tumors at 9 to 12 months of age and, basically, at 100% tumor penetrance (12) . Unlike mammary carcinogenesis induced by neu and H-ras, mammary carcinogenesis induced by MMTV-c-myc or Wnt does not require cyclin D1 because tumors can develop in cyclin D1 knockout mice (4). This is not surprising as c-myc has been shown in several in vitro systems to inhibit cyclin D1 expression (13) (14) (15) (16) (17) and attenuate the cell cycle-dependent cyclin D1 oscillation (18) . Moreover, c-Myc-modulated cell cycle progression does not require cyclin D1 (19) but, instead, can be elicited via induction of cyclin D2 in at least certain cell types (20) (21) (22) (23) . Collectively, these data indicate a possibility that c-Myc and cyclin D1 may mediate mammary carcinogenesis via different pathways. Now the question is whether the c-Myc-mediated and cyclin D1-mediated pathways have any interaction that can result in additive or synergistic effects on tumor progression, such as cell proliferation, invasive ability, and metastasis potential, if both pathways are activated simultaneously.
In this study, we used a benign mouse mammary epithelial cell line (NMuMG) to ectopically overexpress cyclin D1 alone or with c-myc and subsequently tested these cell clones for cell proliferation, anchorage-independent growth in soft agar, and tumorigenesis in SCID mice. Results show that cyclin D1 either alone or in collaboration with c-myc can cause malignant transformation of mouse mammary epithelial cells.
Materials and Methods
Cell lines and plasmids. The mouse mammary epithelial cell line NMuMG obtained from the American Type Culture Collection (Manassas, VA) was used to generate the stably transfected cell clones. NMuMG is generally described as normal mammary epithelial cells in the literature, as it is abbreviated, but we rather consider it a benign cell line. NMuMG cells were cultured in DMEM (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS; Invitrogen) at 37jC and 5% CO 2 . The pcDNA3.1/Neo-CCND1 or pcDNA3.1/Hygro-myc plasmids were used to stably transfect the NMuMG cells to overexpress the murine cyclin D1 and c-myc genes, respectively. The cyclin D1 (Genbank accession no. NM_007631) and c-myc (Genbank accession no. NM_010849) inserts encode the entire cDNA sequence, in addition to franking 5 ¶ untranslated sequence and part of 3 ¶ sequence beyond the stop codon. The constructed plasmids were verified by DNA sequencing. The empty vector was used to generate stable control vector clones.
Single and double transfection. Transfection was done using Lipofect-AMINE 2000 (Invitrogen) according to manufacturer's instructions. Briefly, parental NMuMG cells were cultured in 24-well plates at 80% to 90% confluency. Plasmid DNA (1.0 Ag per well) was fully mixed with 10 AL LipofectAMINE 2000; this mixture was then used to transfect the NMuMG cells. After 24 h of treatment, cells were trypsinized and diluted (1:10 to 1:15) to be replated into 10-cm culture dishes. Culture medium with selection drug (800 Ag/mL neomycin or 400 Ag/mL hygromycin) was changed every 3 to 4 days. Single cell clones were isolated for clone expansion. Each cell clone was screened by reverse transcription-PCR (RT-PCR) and Western blot to determine the exogenous cyclin D1 expression at both mRNA and protein levels. The transfected cell clones were maintained and passaged in culture medium with neomycin (400 Ag/ mL) or hygromycin (200 Ag/mL). After 3 months (about 25 passages), the stably transfected cell clones were used for studies.
Double-stable clones were generated without the lead time, just after four to five passages of cyclin D1 or c-myc stable clones. For double transfection, the pcDNA3.1/Hygro-myc or pcDNA3.1/Neo-CCND1 plasmids were used to transfect the stable clones of cyclin D1 or c-myc, respectively. Similar to single-transfected clones, the double-transfected cell clones were maintained and passaged in culture medium with neomycin (400 Ag/mL) and hygromycin (200 Ag/mL) and used after 20 to 25 passages for in vitro or in vivo experiments.
RNA extraction, RT-PCR, and genotyping. Total RNA was extracted from transfected cells using Trizol reagent (Invitrogen) according to the manufacturer's instruction and stored at À80jC. RT-PCR was used to identify the stable cell clones transfected with cyclin D1 and c-myc using Taqman RT kit (Applied Biosystems, Foster City, CA) and Taq Ready Mixture kit (Sigma, St. Louis, MO). The specific primer pairs for identification of constructed cyclin D1 include an upstream primer located in CCND1 insert (cyclin D1 exon 4, 5 ¶-CTACCGCACAACGCACTTTC-3 ¶) and the downstream primer located in vector (BGH, 5 ¶-TAGAAGGCACAGTCGAGG-3 ¶), which amplified a special RT-PCR product that can only originate from the cyclin D1 expression vector in transfected clones. Similarly, the specific primer pairs were used to identify the mRNA expression of exogenous c-Myc (c-Myc-1F, 5 ¶-CACCGCCTACATCCTGTCCATTCAAGC-3 ¶ and BGH, 5 ¶-TAGAAGGCACAGTCGAGG-3 ¶). The vector control clones were identified by using T7 and BGH primer pairs (T7, 5 ¶-TAATAC-GACTCACTATAGGG-3 ¶; BGH, 5 ¶-TAGAAGGCACAGTCGAGG-3 ¶). Competitive RT-PCR was done to examine the mRNA expression of exogenous and endogenous mRNA expression of cyclin D1, using the same upstream primer (cyclin D1 exon 4, 5 ¶-CTACCGCACAACGCACTTTC-3 ¶), but different downstream primers specific for the endogenous cyclin D1 (D1-E5 stop-r, 5 ¶-TCAGATGTCCA-CATCTCGCACG-3 ¶) or for the exogenous cyclin D1 (BGH, 5 ¶-TAGAAGGCA-CAGTCGAGG-3 ¶). Multiple primer RT-PCR was employed to examine the mRNA expression of exogenous cyclin D1 and c-myc in double stable cell clones, using upstream primers (D1 STOP-F2, 5 ¶-GTGCAGGATGTGGA-CATCTG-3 ¶ and c-Myc-1F, 5 ¶-CACCGCCTACATCCTGTCCATTCAAGC-3 ¶) and the same downstream primer (BGH, 5 ¶-TAGAAGGCACAGTCGAGG-3 ¶). Genotyping by RT-PCR was also done to test the exogenous gene expression in tumors formed from stable cell clones in SCID mice using above primers. Other primers used in semiquantitative RT-PCR and quantitative RT-PCR are listed in Table 1 .
Western blot. Methods for the preparation of protein samples and immunoblotting were described previously (24) . The total protein in cell lysate was quantitated using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Protein aliquots (25 Ag per lane) were electrofractionated on SDS-PAGE and transferred to nitrocellulose membrane for detection by Western blot using rabbit polyclonal anti-cyclin D1 (sc-717; Santa Cruz Biotechnology, Santa Cruz, CA) or anti-c-Myc antibody (sc-20; Santa Cruz Biotechnology), and proteins were visualized by chemiluminescence (Pierce).
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells were seeded in 96-well plate at 1500 cells per 100 AL per well concentration. Cells were grown in culture medium containing either 1.0%, 2.5%, 5.0%, and 10% FBS or 1, 10, and 100 ng/mL epidermal growth factor (EGF) or insulin for 96 h. At the end of incubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (40 AL per well of 5 mg/mL MTT in PBS) was added to each well, and plates were incubated in the dark for 3 h at 37jC. After removal of the medium, the dye crystals were dissolved in isopropanol, and viable cells were detected by reading the absorption at 595 nm in the Ultra plate reader (Tecan Research, Triangle Park, NC). Experiments were repeated thrice in quadruplicate wells to ensure the reproducibility of results. Soft agar growth assay. Anchorage-independent growth was assessed by colony formation in soft agar growth assay. Briefly, equal volumes of agar (1%, DNA grade) and 2Â DMEM (with 20% FBS) were mixed at 40jC to make 0.5% agar in six-well tissue culture plates (Corning, Corning, NY) as a base agar. Cells (0.1 mL, 2.0 Â 10 5 cells per mL) were suspended in 3 mL of 2 Â DMEM (with 20% FBS) and 3 mL of 0.7% agar; 1.5 mL cell suspension was then added in each well (as 0.35% top agar) with final concentration of 5,000 cells per well. Top agar was covered with culture medium. Plates were incubated at 37jC and 5% CO 2 in humidified incubator for 18 days, and medium was changed every 3 to 5 days. Colony formation was observed by light phase contrast and also stained with 0.5 mL of 0.01% Crystal Violet in PBS for 45 min at room temperature followed by photomicrography. Experiments were repeated twice to ensure the reproducibility of our results.
Tumorigenic activity in SCID mouse and histologic examination. Female SCID mice (Taconic, NY) were housed in sterile condition for 1 week before the experiments. At f7 weeks of age, cells (10 7 cells in 0.2 mL PBS) of various NMuMG derived clones were injected into the second/third pair of mammary fat pad of both left and right sides. The number of animals for each cell clone was indicated in details in results. Mice were monitored every alternative day for the development of palpable xenograft tumors. The animals were sacrificed when the xenograft tumors reached the ethical limit (about 15-20 mm in diameter), or when the study was terminated at 19 weeks after injection. In a second set of animal study, we injected cells (10 7 cells) in to the peritoneal cavity of female SCID mice at the age of 7 weeks and sacrificed the mice 8 weeks later. In a third set of animal experiments, cells (10 7 cells) were injected into the left cardiac ventricle of female SCID mice at 9 weeks of age, using the injection procedure described in details by Yin et al. (16) . After scarification, the animals were examined for metastasis in the lung, liver, kidney, and brain, and metastatic tumors were fixed in 10% formalin for further histologic examination. All animal experiments were carried out by strict abidance to the protocols approved by the Animal Investigation Committee of Wayne State University.
Microarray experiments and data analyses. Total cellular RNA was prepared using RNeasy mini kit (Qiagen, Valencia, CA) from two stable clones from each condition (cyclin D1-overexpressing ND5 and ND11, double cyclin D1/c-myc-overexpressing clones-ND5/C23 and ND11/C5, and vector control clones NN2 and NN2/NH2). Assurance of quality assessment and microarray analysis were carried out by personnel in the Applied Genomics Technology Center (Center of Molecular Medicine and Genetics, Wayne State University) and repeated at least twice to ensure the reproducibility and to draw the statistically significant conclusions. Approximately 5 Ag of RNA was used to obtain the cRNA according to standard Affymetrix protocols. The cRNAs were hybridized with the High Density Mouse Genome M430-2 containing 45101 probesets (Affymetrix, Santa Clara, CA). Microarray analysis was done as described previously (25) . Data analysis was done with the GeneSifter and GeneSpring software version 7.2. Expression was normalized against the Affymetrix spike RNA levels as well as against glyceraldehyde phosphate dehydrogenase and actin mRNA levels in all the samples. The expression of genes in cyclin D1 or double-transfected clones with cyclin D1 and c-Myc were compared with the vector control clones as the baseline. Selected candidate genes were confirmed by semiquantitative RT-PCR analysis.
Matrigel invasion assay. The cyclin D1, cyclin D1/c-myc-overexpressing, or vector control cells were suspended at 1 Â 10 6 cells per mL in medium containing DMEM with 0.1% bovine serum albumin, and 100 AL cell suspension was added to the upper well of Transwell inserts coated with 1 mg/mL Matrigel (BD Biosciences, San Jose, CA). In lower wells, 0.6 mL medium containing CXCL12 (10 nmol/L) or vehicle was added. The plates were incubated for 24 h at 37jC in 5% CO 2 . After incubation, the inserts were carefully lifted; cells from the upper surface were gently removed; and the remaining cells at the bottom side of the filter were fixed and stained using the Diff-Quick Staining. The results are expressed as the percentage of cells that invaded the Matrigel and migrated to the bottom side of the Transwell membrane relative to the vector control cells. Each experiment was repeated at least thrice in triplicates to ensure the reproducibility of our results.
Results
Generation of stable cyclin D1, c-myc, or double cyclin D1/cMyc clones. Stable clones of NMuMG cells overexpressing cyclin D1 were generated by transfection with a pcDNA3.1/neo-CCND1 plasmid. NMuMG cells were also transfected with neo-pcDNA3.1 empty vector to establish control cell clones. Results of competitive RT-PCR showed two specific products representing the total mRNA (endogenous + exogenous) and exogenous cyclin D1 in several stable cyclin D1 cell clones, whereas only one specific product representing endogenous cyclin D1 mRNA was seen in the vector control clones. Figure 1A (top) shows the expression of cyclin D1 mRNA and protein in representative cyclin D1 clones ND5 and ND11 as well as vector control clone NN2. Similarly, NMuMG cells were transfected with the pcDNA3.1/Hygro-myc plasmid or empty vector to generate several stable c-myc cell clones and control cell clones. The expression of exogenous c-myc mRNA and protein were shown in Fig. 1A (middle) . Typically, cyclin D1 clone cells showed about 4-to 5-fold higher expression of cyclin D1, whereas c-myc clone cells showed about 5-to 7-fold higher expression levels of c-myc, compared with the corresponding empty vectorexpressing cells. Expression levels remained unchanged after 25 passages, suggesting that exogenous cyclin D1 and c-myc were stably overexpressed.
We further transfected the ND5 and ND11 cells with a pcDNA3.1/Hygro-myc plasmid and selected clones that expressed both cyclin D1 and c-myc. In addition, double-transfected cells were also generated by transfection of c-myc-expressing stable clones with the pcDNA3.1/neo-CCND1 plasmid. The representative clones overexpressing cyclin D1 and c-myc (named ND5/C23, ND11/C2, and ND11/C5) or c-myc-expressing clones transfected with cyclin D1 (named NC2/D1 and NC3/D1) were used in further studies. Figure 1A (bottom) shows the Western blot detection of cyclin D1 and c-Myc proteins in these clones. We also established several stable clones of NMuMG cells expressing both pcDNA3.1-neo and pcDNA3.1hygro empty vectors as controls, such as NN2/ NH2 clone.
Overexpression of cyclin D1 alone changes cell morphology and increases cell growth. We observed that cyclin D1-expressing cells showed changed morphology several days after transfection before the first passage, compared with the empty vector-transfected cells (Fig. 1B) . We used MTT assay to assess the cell proliferation of the cyclin D1-, c-myc-, or double-transfected stable clones by measuring the number of viable cells at different time points. Results showed that overexpression of cyclin D1 alone promoted cell proliferation in the presence of 10%, 5%, and 2.5% serum conditions in a dose-dependent manner compared with the neo-vector control clones, data from representative clones are shown in Fig. 1C (top) . Addition of 1, 10, or 100 ng/mL EGF (Fig. 1C, middle) or insulin (Fig. 1C, bottom) failed to promote the proliferation of cyclin D1-or double cyclin D1 and c-myctransfected cells under low serum (1% FBS) concentration. These data suggest that cyclin D1 is capable of driving proliferation of mouse mammary epithelial cells only at serum concentrations z2.5% indicating that certain serum-derived factors, excluding EGF and insulin, are required to cooperate with cyclin D1 to promote proliferation and tumorigenesis. Similar to cyclin D1 clones, the double cyclin D1 and c-myc-transfected cells also showed increased proliferation compared with vector control (NN2 or NH2) clones (Fig. 1C, top) . On the contrary, c-myc-or c-myc/cyclin D1-overexpressing clones did not show increased number of viable cells compared with vector control clones under 10%, 5%, or 2.5% serum (Fig. 1C, top) . This could be due to increased cell death in these clones compared with cyclin D1 or cyclin D1/c-myc clones because we noticed more floating cells in the wells seeded with the c-myc and c-myc/cyclin D1 clones during our routine microscopic visualization. Furthermore, we determined the phosphorylation status of retinoblastoma protein (pRb) in cyclin D1-or cyclin D1/ c-myc-overexpressing clones; results showed the presence of hyperphosphorylated Rb (ppRb) only in these clones, whereas vector control cells showed both pRb and ppRb (Fig. 1D) .
Overexpression of cyclin D1 leads to malignant transformation of benign mouse mammary epithelial cells. To examine whether overexpression of cyclin D1 alone can cause malignant transformation, an anchorage-independent growth assay in soft agar was employed. A large number of colonies were formed in cyclin D1-overexpressing cells at 18 days after cell seeding, whereas the vector control cells failed to develop colonies. Representative data are presented in Fig. 2A and B. Interestingly, c-myc cell clones (NC2 and NC3) did not develop obvious colonies at the same time point. Other cyclin D1 clones but not c-myc clones also showed anchorageindependent growth correlating to cyclin D1 levels (data not shown).
We then injected cells from ND5 cells into mammary fat pads of five female SCID mice; all mice developed palpable xenograft tumors at both left and right injection sites between 10 and 12 weeks. At 19 weeks when animals were euthanized, the palpable tumors grew about 10 to 12 mm. To confirm these results, in a second set of animal study, we injected cells from three cyclin D1 clones (ND2, ND5, and ND11) to SCID mice (n = 5 mice per clone; two sites). All mice developed palpable tumors between 10 and 13 weeks and reached the ethical limit between 18 and 20 weeks. The tumors showed malignant morphology (Fig. 2C, c) , with some areas of invasion to the surrounding stroma. PCR analyses of these tumor samples showed that the tumors still maintained the high expression of exogenous cyclin D1 (data not shown). Only one of five mice developed a palpable lump (pseudo-tumor, 5 mm in size) at 19 weeks after injection in mice injected with vector control (NN2) cells (Fig. 2C, b ; Table 2A ).
To determine the metastatic potential of the cyclin D1-expressing cells, we also injected ND2, ND5, and ND11 cells into the peritoneal cavity as well as into the left cardiac ventricle (n = 5 mice per clone). Neither tumor seeds were found in the peritoneal cavity nor the macroscopic or microscopic metastasis was discerned in the lung, liver, kidney, or brain after 2 months after injection (Table 2B) .
We also injected two c-myc-expressing cell clones (NC2 and NC3) into mammary fat pads of SCID mice ( five animals per cell clone). Only one of five mice injected with NC2 or NC3 developed very small tumors. Results are summarized in Table 3A . Five mice were also injected with NH2 vector-expressing cells, and none of these mice developed palpable tumors 19 weeks after injection. Overexpression of cyclin D1/c-Myc leads to more aggressive in vitro and in vivo features. Next, we determined whether ectopic expression of c-myc in cyclin D1-overexpressing clones could result in additive or synergistic effects leading to enhanced anchorage-independent growth. Consistent with this notion, our results showed increased colony number and larger colony size of ND5/C23 and ND11/C5 double-expression clones in soft agar compared with the cyclin D1 alone expressing clone. The representative results are shown in Fig. 2A and B. On the other hand, the c-myc-overexpressing clones followed by transfection with cyclin D1 (NC2/D1 or NC3/D1) only showed slightly increased anchorage independent growth in soft agar compared with the c-myc-overexpressing alone clones ( Fig. 2A) .
To access the tumorigeneity of cyclin D1/c-myc cells, we initially injected ND5/C23 cells into the mammary fat pads of five female SCID mice; all mice developed palpable xenograft tumors at both injection sites within 12 to 15 days (Fig. 2C, a) . Because tumors reached the ethical limits, mice were sacrificed between 22 and 28 days after injection. To confirm this result, in a second set of animal study, we injected ND5/C23, ND11/C2, and ND11/C5 cells in SCID mice (n = 5 mice per clone; two sites). All animals developed palpable tumors at 13 to 21 days, and the tumors reached the ethical limit (about 15-20 mm in diameter) between 21 and 34 days. These tumors manifested more aggressive features with highly invasive ability, characterized by a penetrating growth in stromal tissue, chest muscle and adhered to the chest bones; a representative photomicrograph is shown in Fig. 2C, d . PCR analyses of these tumor samples showed that they maintained the overexpression of exogenous cyclin D1 and c-myc. We also inject NC2/D1 and NC3/D1 cells (n = 5 mice per clone; two sites); none of the animals developed any xenograft tumors within 3 months (Table 2A) .
To determine the metastatic potential of the double oncogeneexpressing cells, we injected ND5/C23 and ND11/C5 cells (10 7 cells per animal) into the peritoneal cavity of SCID mice (n = 5 mice per Abbreviation: ND, Not detected. *When tumor can be felt by palpating. cPenetrative growth in the surrounding stroma. bPenetrative growth in the surrounding stroma, chest muscles, and chest bones.
x Indicates number of mice developed tumors (mostly at both injection sites). k One of five mice developed pseudo-tumor in vector control cell (NN2)-injected mice. NOTE: Statistical difference (P) in fold change is shown between D1 and D1/c-myc clones. *Fold change compared with vector control clones. cHighly significant difference between ND5 (D1) and ND5/C23 (D1/c-myc). bSignificant difference between ND5 (D1) and ND5/C23 (D1/c-myc).
x Highly significant difference between ND5 (D1) and ND5/C23 (D1/c-myc).
A. Functional classification of selected genes showing either >10-fold higher or >10-fold lower expression levels in cyclin D1-overexpressing cells compared with cyclin D1/c-myc double-transfected cells
Function Accession no. Genes
Cell adhesion and migration
Serpinb9b Cell growth and proliferation NM_009704 Areg NM_007400 Adam12
Cancer Research
Cancer Res 2007; 67: (8 clone). All animals exhibited many tumor seeds in the peritoneal cavity and abdominal wall with size ranging from 1 to 6 mm when sacrificed 2 months after injection. We then injected ND5/C23 and ND11/C5 cells into the left cardiac ventricle of SCID mice (n = 5 mice per clone) to further determine their metastatic ability. Because some animals showed weak health 9 weeks after injections, we terminated the study at this time point. Seven mice were found to have three to five spots of metastatic tumor spots on the lung surface, varying between 1 and 3 mm in diameter. Histologic examination confirmed the existence of multiple metastatic tumor foci/nodules in the lung (Fig. 2C, f; Table 2B ). No lung metastasis was found in the remaining three mice. But in one of the mice, a large chest tumor and many tumor seeds were found on the chest walls and diaphragm (Fig. 2C, e) , indicating that the cells were misrouted into the chest cavity of this mouse instead of the left cardiac ventricle.
We also injected NN2/NH2 cell clone that expressing both neoand hygro-pcDNA3.1 empty vectors into mammary fat pads of five SCID mice (two injection sites per animal). Only one of five mice developed palpable pseudo-tumor (5 mm) when sacrificed 14 weeks after injection, with histology similar to the pseudo-tumor from NN2 cells described above (Fig. 2C, b) .
Gene expression profile in single-or double-transfected cell clones. To identify the molecular pathways mediating the effect of cyclin D1 and cyclin D1/c-myc, we used cDNA microarray to determine the expression profile of two cyclin D1-overexpressing clones (ND5 and ND11) and two double-transfected (ND5/C23 and ND11/C5) clones as well as their corresponding control clones. Figure 3A shows the proportion of genes that are similar or different in cyclin D1 and cyclin D1/c-myc clones. The signal values were calculated from the multiple probes present on each chip as described earlier (25) , and each chip was repeated twice to draw a statistically significant data.
Selected expressed genes (>10-fold higher or >10-fold lower gene expression levels) were categorized based on their functional properties and are presented in Table 3A . We selected candidate genes from microarray data for further verification of their expression by RT-PCR ( Fig. 3B; Table 3B ). This selection was based on results in the literature indicating a direct or indirect role for each candidate gene in invasion/migration, proliferation, or signal transduction. The most strikingly differential expression between cyclin D1 and cyclin D1/c-myc clones was observed in genes related to invasion and migration ( Fig. 3B and C) . The cyclin D1-expressing cells showed up-regulated CXCL12, CXCR4, MMP-2, and MMP-12, whereas the double-expressing cells exhibited upregulation of Snail homologue 2 (Snail2 or Slug) and significant down-regulation or complete loss of E-, N-, K-, L-, and P-cadherin and epithelial tight junction protein claudin 2 (Cldn2). Collectively, these results suggest that cyclin D1 and co-overexpressed cyclin D1/c-myc may use distinct pathways for the invasion (as observed in our xenograft model).
We further validated the microarray and RT-PCR data and tested the functionality of some of the genes related to invasion and migration. Cyclin D1-and cyclin D1/c-myc-overexpressing and vector control clones were subjected to Matrigel chemoinvasion assay to check the possible differences between these two conditions. Cyclin D1 clones (ND5 and ND11), which expressed CXCR4, showed significantly increased (P < 0.001) chemoinvasion against CXCL12 compared with either double cyclin D1/c-myc (which did not express CXCR4) or vector control clones (Fig. 3D) . Although cyclin D1/c-myc cells showed increased chemokinesis, they could not pass through the pores of Transwell membrane. Figure 3D (middle) show that cyclin D1/c-myc cells are stuck in pores rather than passing through it, unlike cyclin D1-overexpressing cells that pass through the pores to the bottom side of the filter.
Discussion
Literature on ectopic overexpression of cyclin D1 shows conflicting data. Cyclin D1-overexpressing rat fibroblasts are reported to show accelerated G 1 -S phase transition in a growth factor-dependent manner without obvious signs of transformation (9, 26) , whereas Pagano et al. (27) reported that cyclin D1 overexpression prevented normal fibroblasts from entering S phase. Constitutive expression of cyclin D1 has also been shown to sensitize cells to radiation, serum starvation, and retinoic acidinduced cell death (27) (28) (29) . Now in this study, we add one more conflict in the literature by showing, for the first time, clear in vitro and in vivo evidence that overexpression of wild-type cyclin D1 can drive cell proliferation and cause malignant transformation of benign mouse mammary epithelial cells, which leads to invasive tumor growth in SCID mice. It is noteworthy that the proliferative potential of cyclin D1-overexpressing stable clones depends on serum concentrations z2.5%, indicating that some serum factors, but not insulin and EGF, are needed to assist cyclin D1. With regard to the tumorigenic and invasive phenotypes of cyclin D1-overexpressing cells, we cannot rule out the possibility that during generation of stable cell clones, additional genetic changes may have accumulated and are likely to influence the tumorigenic or invasive phenotypes of cyclin D1-overexpressing clones. We observed that cyclin D1-and cyclin D1 plus c-myc-overexpressing clones showed increased phosphorylation of pRb. Thus, deregulation of Rb phosphorylation status may be one of the mechanisms for cell growth and malignant transformation in cyclin D1-overexpressing cells.
In our system, c-myc-overexpressing clones hardly formed colonies (only few colonies) in soft agar at the time when cyclin D1 cells already formed a number of large colonies. Consistent with these in vitro data, only 2 of 10 SCID mice injected with c-mycexpressing cells developed very small xenograft tumors with long latency, in strong contrast to the 100% xenograft tumor penetrance from cyclin D1-expressing cell clones. We concluded that cyclin D1 is more potent than c-myc in malignant transformation of benign mouse mammary epithelial cells.
Another finding of our study is that c-myc collaborates with cyclin D1 in driving cell growth to form more aggressive xenograft tumors in SCID mice. Interestingly, this only occurs in cyclin D1 stable clones transfected with c-myc (i.e., cyclin D1/c-myc cells) not in the c-myc stable clones transfected with cyclin D1 (i.e., c-myc/ cyclin D1 cells). The c-myc/cyclin D1 cells show only slight growth in soft agar and do not form tumors in SCID mice, at least not as early as the cyclin D1/c-myc cells or until the termination of experiment. These results suggest that the sequence of hit may be an important determinant for deciding the cell fate, and that initial insult or existing cellular milieu plays a prominent role in determining the transforming potential of a cell. These results provide very important insights to explain some of the conflicting results seen in experiments with cyclin D1 overexpression and suggest that the cellular milieu may play a critical role.
The microarray analysis of cyclin D1-and cyclin D1/c-mycoverexpressing cell clones revealed a high degree of unique differential expression of invasion and metastatic-related genes. The cyclin D1-transfected clones showed up-regulation of CXCL12, CXCR4, MMP-2, and MMP-12, whereas the cyclin D1/c-mycexpressing clones showed up-regulation of Snail2 and significant down-regulation to complete loss of E-, N-, K-, L-, and P-cadherin and epithelial tight junction protein Cldn2. The Snail family of transcription factors has been implicated in cellular acquisition of invasive and migratory properties following repression of the adhesion protein E-cadherin (30) (31) (32) (33) (34) . In addition, studies have shown the presence of high levels of Snail/Slug protein in invasive mouse and human carcinoma cell lines and tumors in which E-cadherin expression has been lost (35) (36) (37) . In human breast cancer, Slug was elevated with increasing tumor grade and prognostic indices (33, (38) (39) (40) (41) . Consistent with these reports, our results in SCID mice provide evidence that that double-transfected cells were highly invasive and metastatic, which could be attributed to inversely expressed snail and E-cad genes. High expression of CXCL12, CXCR4, MMP-2, and MMP-12 in the cyclin D1 cell clone may be responsible for its invasive phenotype (42, 43) , although mechanistic studies are required to confirm these findings. Fernandes et al. (42) have shown that MMP-2 expression was regulated by CXCL12, which has also been implicated in cancer cell invasion. The CXCL12/CXCR4 axis has also been implicated in mediating angiogenesis (44) and cell survival (45) . Recently, Schmid et al. (46) have shown CXCL12 and CXCR4 expression in human ductal carcinoma in situ and atypical ductal hyperplasia as well as elevated levels in concurrent invasive disease. Our data indicate that introduction of ectopic c-Myc in cyclin D1-transfected cells down-regulates the CXCL12/CXCR4 pathway but up-regulates the Snail2/E-cadherin axis for invasion.
Collectively, the novelty and significance of these results are that overexpression of cyclin D1 was able to transformation of murine mammary epithelial cells from a benign to a malignant status. Additional overexpression of c-myc in cyclin D1-transformed cells makes the tumor more aggressive, as previously hypothesized (11, 24, 47) . Cyclin D1 expression alone and cyclin D1/c-myc dual expression may use different molecular pathways to elicit invasion ability.
